NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy (Q36809405)
Jump to navigation
Jump to search
scientific article published on 14 November 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy |
scientific article published on 14 November 2012 |
Statements
1 reference
NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy (English)
1 reference
Junichi Azuma
1 reference
Masako Ohno
1 reference
Ryuji Kubota
1 reference
Soichiro Yokota
1 reference
Takayuki Nagai
1 reference
Kazunari Tsuyuguchi
1 reference
Yasuhisa Okuda
1 reference
Tetsuya Takashima
1 reference
Sayaka Kamimura
1 reference
Yasushi Fujio
1 reference
Ichiro Kawase
1 reference
Pharmacogenetics-based tuberculosis therapy research group
1 reference
14 November 2012
1 reference
1 reference
1091-1101
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference